Together, these studies suggest that the toxicities associated with the treatment of Mdm2 inhibitors are caused by deregulated p53 activation when Mdm2-mediated regulation of p53 is disrupted in normal tissues and that other approaches to achieve therapeutic reactivation of p53-mediated tumor suppression in cancer patients should be explored. Here, TP53 is linked to cancer.